These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 21710840)
21. Another ingredient added to HER2 mix. Titus K CAP Today; 1999 Nov; 13(11):1, 20-4, 26 passim. PubMed ID: 10724678 [No Abstract] [Full Text] [Related]
22. [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option]. Ito Y Gan To Kagaku Ryoho; 2010 Dec; 37(13):2845-9. PubMed ID: 21235090 [No Abstract] [Full Text] [Related]
23. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Ross JS Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168 [TBL] [Abstract][Full Text] [Related]
25. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Whenham N; D'Hondt V; Piccart MJ Clin Breast Cancer; 2008 Feb; 8(1):38-49. PubMed ID: 18501058 [TBL] [Abstract][Full Text] [Related]
26. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390 [No Abstract] [Full Text] [Related]
27. HER2 and surgery: more questions to answer. Spigel DR Lancet; 2003 Aug; 362(9383):502-3. PubMed ID: 12932377 [No Abstract] [Full Text] [Related]
28. HER2-positive advanced breast cancer. Robert NJ; Favret AM Hematol Oncol Clin North Am; 2007 Apr; 21(2):293-302. PubMed ID: 17512450 [TBL] [Abstract][Full Text] [Related]
29. Proceedings of the HER2 State of the Art Conference. 21-23 November 1999. Montreux, Switzerland. Ann Oncol; 2001; 12 Suppl 1():1-107. PubMed ID: 11816498 [No Abstract] [Full Text] [Related]
31. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. Cameron DA; Stein S Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499 [TBL] [Abstract][Full Text] [Related]
32. Trastuzumab in CNS progressive metastatic breast cancer. Tosoni A; Franceschi E; Esposti RD; Brandes AA Future Oncol; 2007 Aug; 3(4):367-9. PubMed ID: 17661709 [No Abstract] [Full Text] [Related]
33. Treatment of metastatic breast cancer: looking towards the future. Amar S; Roy V; Perez EA Breast Cancer Res Treat; 2009 Apr; 114(3):413-22. PubMed ID: 18465221 [TBL] [Abstract][Full Text] [Related]
34. Does trastuzumab increase the risk of isolated CNS metastases in patients with breast cancer? Abrey LE Nat Clin Pract Neurol; 2006 Jun; 2(6):302-3. PubMed ID: 16932571 [No Abstract] [Full Text] [Related]
35. Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000. Semin Oncol; 2001 Oct; 28(5 Suppl 16):1-153; quiz 154-65. PubMed ID: 11760720 [No Abstract] [Full Text] [Related]
36. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Mass RD; Press MF; Anderson S; Cobleigh MA; Vogel CL; Dybdal N; Leiberman G; Slamon DJ Clin Breast Cancer; 2005 Aug; 6(3):240-6. PubMed ID: 16137435 [TBL] [Abstract][Full Text] [Related]
37. Current perspective - trastuzumab. Hall PS; Cameron DA Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123 [TBL] [Abstract][Full Text] [Related]
38. Trastuzumab in the treatment of breast cancer. Hortobagyi GN N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745 [No Abstract] [Full Text] [Related]
39. ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). Clin Adv Hematol Oncol; 2003 Apr; 1(4):237. PubMed ID: 16224413 [No Abstract] [Full Text] [Related]
40. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective. Kulkarni S; Hicks DG Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]